Nchi: Australia
Lugha: Kiingereza
Chanzo: Department of Health (Therapeutic Goods Administration)
adenosine, Quantity: 10 mg
Juno Pharmaceuticals Pty Ltd
Injection, solution
Excipient Ingredients: sodium chloride; water for injections
Intravenous
6, 10, 5
(S4) Prescription Only Medicine
Intravenous ADENOSINE JUNO is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging, in patients unable to exercise adequately.
Visual Identification: A clear colourless solution free from visible particles filled in 10mL, clear glass vial, stoppered with 13mm red or grey colour serum chloro butyl stopper and sealed with flip off aluminium seals; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2018-07-31
Adenosine Juno Consumer Medicine Information Juno Pharmaceuticals Pty Ltd 1 ADENOSINE JUNO _Adenosine _ CONSUMER MEDICINE INFORMATION (CMI) WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Adenosine Juno. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given this medicine against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. WHAT ADENOSINE JUNO IS USED FOR Adenosine Juno is used as an aid to doctors, to understand how your heart is working. Adenosine Juno is used during radionuclide imaging of your heart. Adenosine Juno is given to you before the radionuclide (the agent which allows them to see your heart). Adenosine Juno works by opening up your heart's blood vessels to allow blood to flow more freely and can then be seen more clearly by doctors. Adenosine Juno is only given in hospitals. It is given to you as an injection. Your doctor, however, may prescribe Adenosine Juno for another purpose. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY IT HAS BEEN PRESCRIBED FOR YOU. This medicine is only available with a doctor's prescription. This medicine is not addictive. BEFORE YOU ARE GIVEN IT WHEN YOU MUST NOT BE GIVEN IT DO NOT RECEIVE ADENOSINE JUNO IF YOU HAVE: • asthma or any other lung disease • recently had a heart transplant • some other problems with your heart or heart rhythm • severe low blood pressure DO NOT RECEIVE ADENOSINE JUNO IF YOU ARE ALLERGIC TO IT OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET. Some symptoms of an allergic reaction include skin rash, itching, shortness of breath or swelling of the face, lips or tongue, which may cause difficulty in swallowing or breathing. BEFORE YOU ARE GIVEN IT TELL YOUR DOCTOR IF YOU HAVE ALLERGIES TO: - ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET - ANY OTH Soma hati kamili
Australian Product Information Page | 1 AUSTRALIAN PRODUCT INFORMATION ADENOSINE JUNO (ADENOSINE)_ _ _ _ 1 NAME OF THE MEDICINE Adenosine 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Adenosine Juno is a sterile solution for intravenous infusion, provided in clear glass vials. Each vial contains 30 mg of adenosine in 10 mL of a 0.9% w/v solution of sodium chloride in sterile water for injections. The pH is between 4.5 and 7.5. For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS 3. PHARMACEUTICAL FORM Adenosine is a white crystalline powder slightly soluble in water. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Intravenous Adenosine Juno is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging, in patients unable to exercise adequately. 4.2 DOSE AND METHOD OF ADMINISTRATION Adenosine Juno is intended for use in hospitals, where facilities for cardiac monitoring and resuscitation are available. Product is for single use in one patient only. Discard any residue. DIAGNOSTIC DOSE ADULTS 1. Adenosine Juno should be administered undiluted as a continuous peripheral intravenous infusion at a dose of 140 µg/kg/min over fixed time interval of six minutes (total dose 0.84 mg/kg) using an infusion pump. Separate venous sites for Adenosine Juno and radionuclide administration are recommended to avoid an adenosine bolus effect. 2. After three minutes of Adenosine Juno infusion, the radionuclide is injected. 3. Heart rate and blood pressure should be recorded at 1 minute intervals, and ECG should be monitored continuously during Adenosine Juno infusion. To avoid an adenosine bolus effect, blood pressure should be measured in the arm opposite to the Adenosine Juno infusion. The table below is given as a guide for adjustment of the infusion rate of undiluted Adenosine Juno, in line with body weight (total dose 0.84 mg/kg). Australian Product Information Page | 2 Patient Weight Infusion Rate _(kg) _ _(mL/min) _ 45-49 2.1 50-54 2.3 55-59 2.6 60-64 2.8 65-69 3.0 70-74 3.3 75 Soma hati kamili